New Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-KO Neurons
Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism, results from the loss of expression of the Fmr1 gene which encodes the RNA-binding protein FMRP (Fragile X Mental Retardation Protein). Among the thousands mRNA targets of FMRP, numerou...
Gespeichert in:
Veröffentlicht in: | Frontiers in molecular neuroscience 2018-09, Vol.11, p.342-342 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism, results from the loss of expression of the Fmr1 gene which encodes the RNA-binding protein FMRP (Fragile X Mental Retardation Protein). Among the thousands mRNA targets of FMRP, numerous encode regulators of ion homeostasis. It has also been described that FMRP directly interacts with Ca2+ channels modulating their activity. Collectively these findings suggest that FMRP plays critical roles in Ca2+ homeostasis during nervous system development. We carried out a functional analysis of Ca2+ regulation using a calcium imaging approach in Fmr1-KO cultured neurons and we show that these cells display impaired steady state Ca2+ concentration and an altered entry of Ca2+ after KCl-triggered depolarization. Consistent with these data, we show that the protein product of the Cacna1a gene, the pore-forming subunit of the Cav2.1 channel, is less expressed at the plasma membrane of Fmr1-KO neurons compared to WT. Thus, our findings point out the critical role that Cav2.1 plays in the altered Ca2+ flux in Fmr1-KO neurons, impacting Ca2+ homeostasis of these cells. Remarkably, we highlight a new phenotype of cultured Fmr1-KO neurons that can be considered a novel cellular biomarker and is amenable to small molecule screening and identification of new drugs to treat FXS. |
---|---|
ISSN: | 1662-5099 1662-5099 |
DOI: | 10.3389/fnmol.2018.00342 |